{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:47:02Z","timestamp":1760986022639},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,30]]},"DOI":"10.7759\/cureus.16074","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T01:40:09Z","timestamp":1625103609000},"source":"Crossref","is-referenced-by-count":1,"title":["New-Onset Refractory Status Epilepticus (NORSE) as a Recurrence of Anti-Neuronal Nuclear Antibody 2 (ANNA-2) Encephalitis After Immune Checkpoint Inhibition Therapy"],"prefix":"10.7759","author":[{"given":"Danielle","family":"Pitter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mejico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius G","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Cuello-Oderiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010787","article-title":"New-onset super-refractory status epilepticus: a case series of 26 patients","volume":"95","author":"Matthews E","year":"2020","unstructured":"Matthews E, Alkhachroum A, Massad N, Letchinger R, Doyle K, Claassen J, Thakur KT. New-onset super-refractory status epilepticus: a case series of 26 patients. Neurology. 2020, 95:e2280-5. 10.1212\/WNL.0000000000010787","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.02.003","article-title":"Survey of the diagnostic and therapeutic approach to new-onset refractory status epilepticus","volume":"46","author":"Cabrera Kang CM","year":"2017","unstructured":"Cabrera Kang CM, Gaspard N, LaRoche SM, Foreman B. Survey of the diagnostic and therapeutic approach to new-onset refractory status epilepticus. Seizure. 2017, 46:24-30. 10.1016\/j.seizure.2017.02.003","journal-title":"Seizure"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10518","article-title":"Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments","volume":"53","author":"Pittock SJ","year":"2003","unstructured":"Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003, 53:580-7. 10.1002\/ana.10518","journal-title":"Ann Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.2.437","article-title":"Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus","volume":"124","author":"Bataller L","year":"2001","unstructured":"Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001, 124:437-43. 10.1093\/brain\/124.2.437","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1173","article-title":"Adult-onset opsoclonus-myoclonus syndrome","volume":"69","author":"Klaas JP","year":"2012","unstructured":"Klaas JP, Ahlskog JE, Pittock SJ, et al.. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012, 69:1598-607. 10.1001\/archneurol.2012.1173","journal-title":"Arch Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0026-1","article-title":"Opsoclonus-myoclonus syndrome in an adult with malignant melanoma","volume":"253","author":"Jung KY","year":"2006","unstructured":"Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol. 2006, 253:942-3. 10.1007\/s00415-006-0026-1","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4607","article-title":"Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies","volume":"73","author":"Armangu\u00e9 T","year":"2016","unstructured":"Armangu\u00e9 T, Sabater L, Torres-Vega E, et al.. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016, 73:417-24. 10.1001\/jamaneurol.2015.4607","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjy365","article-title":"Paraneoplastic opsoclonus-myoclonus syndrome as a rare presentation of breast cancer","volume":"2019","author":"Martins L","year":"2019","unstructured":"Martins L, Galv\u00e3o D, Silva A, Vieira B, Reis \u00d3, Vitorino R, Pires P. Paraneoplastic opsoclonus-myoclonus syndrome as a rare presentation of breast cancer. J Surg Case Rep. 2019, 2019:rjy365. 10.1093\/jscr\/rjy365","journal-title":"J Surg Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.17659\/01.2017.0033","article-title":"Rare paraneoplastic opsoclonus myoclonus syndrome (POMS) in a recurrent breast cancer patient: importance of early recognition of POMS and initiation of rehabilitation intervention","volume":"7","author":"Mar SH","year":"2017","unstructured":"Mar SH, Ling TP, Yeow Leng T. Rare paraneoplastic opsoclonus myoclonus syndrome (POMS) in a recurrent breast cancer patient: importance of early recognition of POMS and initiation of rehabilitation intervention. JCR. 2017, 7:119-23. 10.17659\/01.2017.0033","journal-title":"JCR"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002534","article-title":"New-onset refractory status epilepticus (NORSE)","volume":"21","author":"Mantoan Ritter L","year":"2021","unstructured":"Mantoan Ritter L, Nashef L. New-onset refractory status epilepticus (NORSE). Pract Neurol. 2021, 21:119-27. 10.1136\/practneurol-2020-002534","journal-title":"Pract Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.44.12.2241","article-title":"Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity","volume":"44","author":"Dalmau J","year":"1994","unstructured":"Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology. 1994, 44:2241-6. 10.1212\/wnl.44.12.2241","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410290303","article-title":"Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer","volume":"29","author":"Luque FA","year":"1991","unstructured":"Luque FA, Furneaux HM, Ferziger R, et al.. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991, 29:241-51. 10.1002\/ana.410290303","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.06.016","article-title":"Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study","volume":"110","author":"Brieva-Ru\u00edz L","year":"2008","unstructured":"Brieva-Ru\u00edz L, Diaz-Hurtado M, Matias-Guiu X, M\u00e1rquez-Medina D, Tarragona J, Graus F. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clin Neurol Neurosurg. 2008, 110:1044-6. 10.1016\/j.clineuro.2008.06.016","journal-title":"Clin Neurol Neurosurg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1851517","article-title":"Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition","volume":"9","author":"Urban H","year":"2020","unstructured":"Urban H, Willems LM, Ronellenfitsch MW, Rosenow F, Steinbach JP, Strzelczyk A. Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition. Oncoimmunology. 2020, 9:1851517. 10.1080\/2162402X.2020.1851517","journal-title":"Oncoimmunology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.04.054","article-title":"New-onset refractory status epilepticus (NORSE)--the potential role for immunotherapy","volume":"47","author":"Khawaja AM","year":"2015","unstructured":"Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)--the potential role for immunotherapy. Epilepsy Behav. 2015, 47:17-23. 10.1016\/j.yebeh.2015.04.054","journal-title":"Epilepsy Behav"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54491-new-onset-refractory-status-epilepticus-norse-as-a-recurrence-of-anti-neuronal-nuclear-antibody-2-anna-2-encephalitis-after-immune-checkpoint-inhibition-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:26Z","timestamp":1707507086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54491-new-onset-refractory-status-epilepticus-norse-as-a-recurrence-of-anti-neuronal-nuclear-antibody-2-anna-2-encephalitis-after-immune-checkpoint-inhibition-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.16074","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,30]]}}}